Kornimate/medical-research-clean huggingface dataset:
randomized pilot study evaluating isopropyl alcohol and uvc rays in disinfection of cell phones

Conditions: Cross Infection

Summary: cell phones have become a fundamental accessory of our lives and clinical practice, often kept in contact with the body. since most modern smartphones are equipped with touch screens, they can serve the function of reservoirs for pathogenic microorganisms; moreover, they can be the means of transmission of such microorganisms from the environment to humans. a number of observational studies are available in the literature evaluating the effectiveness of various sanitization methods in reducing the bacterial load of high-touch devices, both chemical and physical. to our knowledge, no real-world evidence is available comparing the residual effect of the two methods on the bacterial load of cell phones, since all available studies are carried out in the laboratory, with inoculums of predetermined bacterial loads whose suppression by the disinfectant is monitored over time, and involve laptops, tablets and keyboards.


Eligibility criteria:
inclusion criteria: * be a healthcare provider in the departments of neonatology, geriatric internal medicine, nephrology, anesthesia, resuscitation, intensive care unit at fondazione policlinico universitario "a.gemelli" irccs * own a smartphone * carry one's smartphone for the duration of the work shift (8 hours) * give consent to participate in the study * be willing to report 3 hours after sanitisation for follow-up sampling exclusion criteria: * not to be a healthcare worker in the departments of neonatology, geriatric internal medicine, nephrology, anesthesia, resuscitation, intensive care unit at fondazione policlinico universitario "a.gemelli" irccs * not to be on work shift during surveys * not to carry one's smartphone for the duration of the work shift (8 hours) * not to give consent to participate in the study * not to be willing to report 3 hours after sanitisation for follow-up sampling

Keywords: cross infection high touch surfaces cellphone disinfection isopropyl alcohol uvc
evaluation of quality of care - haemodialysis public-private-partnership, hospital authority

Conditions: End-stage Renal Failure (ESRF)

Summary: patients with end-stage renal failure (esrf) have lost the function to excrete urea and maintain electrolyte balance, which is lethal unless they are given renal replacement therapy (gibney, hoste et al. 2008). as one of the initiatives of service improvement, the ha has introduced the haemodialysis public-private partnership (hd ppp) programme to shorten the waiting time for patients with esrf needing hd treatment. hd ppp programme is a new service provision model that purchases healthcare services from non-government healthcare organizations. the evaluation on the quality of care (qoc) is an essential part of the programme in order to inform future policy. the department of family medicine and primary care of the university of hong kong has been appointed by the ha to carry out the evaluation of the qoc of the programme. the action learning and audit spiral methodologies to measure whether the target standard of care intended by the hd ppp programme is achieved. each hd ppp participating hospitals and centers will be invited to complete a structure evaluation questionnaire. sixty patients who have agreed to join hd ppp and 60 control patients who have refused to take part in hd ppp will be included. the participants will be followed up by telephone to evaluate the effect of the programme on quality of life (qol), patient enablement, and global rating of change in health condition. data on the process of care and clinical outcomes of care will be retrieved from the ha medical records. main outcome measures: the primary outcomes are the proportion of participants who have received the planned process of care and adequate haemodialysis (hd) measured by the kt/v data analysis: descriptive statistics on proportions meeting the qoc criteria will be calculated. the outcomes of hd ppp subjects will be compared at 6, 12, 24, 36 and 48 months by paired sample t-test. the outcomes between hd ppp subjects and control group will be compared by independent sample t-test or chi-square test. results: the qoc of the hd ppp programme will be determined. areas of deficiency and possible areas for quality enhancement will be identified. conclusion: the results of this study will provide empirical evidence on whether the hd ppp can achieve equivalent qoc as the usual ha care in order to guide service planning and policy decision making for patients with esrf.


Eligibility criteria:
inclusion criteria: * patients currently being followed up at the ha on haemodialysis, peritoneal dialysis, or are new esrf cases will be recruited. exclusion criteria: * patients who do not have a good vascular access, are not hemodynamically stable for hd, are not mentally sound, ambulatory and independent, are unable to understand and communicate in chinese language, or refuse to give consent will be excluded from the hd ppp programme.

Keywords: end-stage renal failure (esrf)
mr elastography parameters impact on mr-hifu efficacy in uterine fibroids

Conditions: Uterine Fibroid

Summary: magnetic resonance (mr)-guided high-intensity focused ultrasound (hifu) ablation for fibroids is an outpatient approach for controlling symptom with an excellent safety record. it is important to exclude in advance patients who would not benefit from this treatment. for that purpose this study assesses the influence of fibroid elasticity and diffusion on ablation efficiency during treatment by mr-hifu

pre-procedural predictors of treatment efficacy will be useful for excluding in advance patients who would not get benefit of this treatment. it seems that elastography, cellular density and perfusion could be considered as predictors. fibroid elastography will be quantified by mre resoundant® system and pelvic ultrasound. perfusion and cellular density will be quantified by mr diffusion.

Eligibility criteria:
inclusion criteria: * woman * aged more than 18 years * not postmenopausal * having one or two symptomatic fibroid with size \< 15cm. * leiomyoma type funaki 1 or 2 on pre-therapeutic mri * normal cervicovaginal smear performed within 2 years prior to inclusion * myoma technically accessible to mr-hifu treatment verified on pre-therapeutic mri * sss score on ufs-qol ≥ 10 * signed informed consent prior to any study related procedure * with a medical insurance exclusion criteria: * contraindicated to mr examination, gadolinium contrast injection (pregnancy etc..). * presence or suspicious of pelvic malignant tumor * myomas causing haemorrhage (meno-metrorrhagia) associated with anemia (hb \<10g/dl) * pregnant or lactating woman * small submucous myoma accessible for hysteroscopic treatment. * active pelvic infection * presence of calcification, surgical staples, or rigid implant in the passage of the ultrasound beamo people placed under legal protection, or participating in another research protocol including an exclusion period still in progress at pre-inclusion.

Keywords: hifu fibroid treatment mr elastography perfusion diffusion weighted imaging arfi fibroid stiffness
microassay and allergy skin prick test correlation study

Conditions: Allergy Pollen

Summary: the purpose of this study is to evaluate the potential correlation of the results of allergen-specific skin prick tests (spt) to that of allergen-specific microarray determination (microassay test). subjects who meet enrollment criteria, after signing an irb approved consent form, will perform a minor finger prick blood draw and blot to be mailed off for microassay analysis. specific statistical analysis will be done to assess all potential correlations between spt and microassay. this study design should enable assessment of the level of correlation between spt results and microassay results for specified allergens within a cohort of subjects with allergic rhinitis.

prospective subjects for study entry will initially be screened by the results of their allergy skin test that were acquired within the past two years. in order to be a prospective subject positive spt results of five of the following ten allergens will be required: dust mite, ragweed, cat dander, johnson grass, bermuda grass, timothy grass, oak, cladosporium, dog dander, and cockroach. after signing an irb approved consent form, these patients will undergo a finger prick blood draw and blot. this study will be conducted in compliance with the protocol, gcp and applicable regulatory requirements. subjects 18 years of age or over who have never initiated a course of allergy immunotherapy or have not completed more than three months of scit immunotherapy will be enrolled. sub-investigator(s) will screen patient charts from a database of patients previously tested using the uas protocol. patients that qualify based on inclusion criteria will be contacted by phone and asked if they would be willing to participate in this study. subject arrives to the clinic and all inclusion and exclusion criteria are verified by their primary physician and the sub-investigator. sub-investigator insures that the irb verified consent form is signed and that the patient has no questions. subject or sub-investigator will perform the finger prick and blot using the instructions listed on the allergenex sample collection packet. the sample will be mailed to spiriplex to be analyzed using their microarray device. the microassay results will be sent to the primary investigation site for correlation analysis with the previously logged spt results. these results will be blinded to the statisticians and researchers that will be determining potential correlation between spt and microassay results.

Eligibility criteria:
inclusion criteria: * subjects 18 years of age or over who have never initiated a course of allergy immunotherapy or have not completed more than three months of subcutaneous immunotherapy will be enrolled. exclusion criteria: * subjects with bleeding disorders or a history of vasovagal reactions to blood draws will not be enrolled in this study.

Keywords: skin test, microarray test
pk study of aripiprazole im depot for chinese patients with schizophrenia

Conditions: Schizophrenia

Summary: this study assess pharmacokinetics and safety of multi-administration of aripiprazole im depot formulation at doses of 400mg in patients with schizophrenia.

to evaluate the pharmacokinetics and safety of aripiprazole prolonged im depot 400mg administered to chinese adult subjects with schizophrenia every four weeks for 20 consecutive weeks

Eligibility criteria:
inclusion criteria: 1. subjects, and their legal representatives(or their guardian ), who have signed the informed consent form(icf); 2. patients with a diagnosis of schizophrenia as defined by dsm-iv-tr (295.30, 295.10, 295.20,295.90 , 295.60); 3. subjects, both male and female, who are at age between 18 and 64 (also including 18 and 64 years of age) at time of informed consent. exclusion criteria: 1. presence of other mental disorders than schizophrenia confirmed through diagnostic criteria of dsm-iv-tr; 2. subjects who are alcoholomania or independent of drug, or have drug abuse history; 3. positive for any of hiv antibody, hbsag, hcv antibody and syphilis serology testing; other protocol-defined inclusion and exclusion criteria may apply.
pet-imaging of unruptured intracranial aneurysm inflammation

Conditions: Intracranial Aneurysm; Cerebral Aneurysm; Inflammation

Summary: the main purpose of this study is to determine if pet-imaging can be used to evaluate inflammation level of intracranial aneurysms, thus helping to evaluate the rupture risk of intracranial aneurysm.

study subjects are patients who are diagnosed with an unruptured saccular intracranial aneurysm and planned for elective surgical treatment of intracranial aneurysms. prior the planned surgery, all study subjects will undergo pet-imaging of the brain with 18f-fdg- and 68ga-dotanoc-tracers targeting glucose metabolism and somatostatin receptors in inflammatory cells. after pet-imaging, samples for histopathological examination from the intracranial aneurysm sac will be collected during the surgery from every study subject. blood samples are collected prior to aneurysm operation from the routine pre-operative laboratory tests. cerebrospinal fluid samples are collected during the surgical procedure from the surgical site. from blood samples we will evaluate expression of 20 different circulating micrornas (mirna) and the level of tumor necrosis factor-1, interleukin 1 beta, vascular endothelial growth factor, and evaluate correlations between mirna expression and suvmax in pet-imaging and mirna and aneurysm histological findings. correlation between inflammatory findings in histological studies and pet-imaging will be evaluated (correlation of suvmax to aneurysm histological findings).

Eligibility criteria:
inclusion criteria: * fusiform intracranial aneurysms * following medications: asetylsalisylic acid or non-steroidal anti-inflammatory drugs. * patients who have contraindication for magnetic resonance imaging (pace makers, foreign ferromagnetic bodies or implants) * patients who are allergic to contrast agents. * pregnancy * underage persons * patients on somatostatin analogue medication or with known neuroendocrine tumor exclusion criteria: * patients who are diagnosed with unruptured intracranial aneurysm with mri/mra or dsa * patients who are planned to undergo surgical treatment (ligation) of the intracranial aneurysm * age ≥18 and \<75 years. * saccular intracranial aneurysm with maximum diameter ≥ 3 mm.

Keywords: intracranial aneurysm pet inflammation positron emission tomography rupture risk
evaluation of volatile induction and maintenance anesthesia (vima) with sevorane in adult patients required general anesthesia for surgery in terms of quality of anesthesia and its influence on cardiovascular system in common clinical practice

Conditions: Anesthesia, General

Summary: the main objective of this post-marketing observational study is to collect data from the use of general anesthesia in patients undergoing any surgery to create local recommendations. these data will be based on the evaluation of volatile induction and maintenance anesthesia (vima) with sevorane® (sevoflurane) in adult patients requiring general anesthesia for surgery in terms of quality of anesthesia and its influence on cardiovascular system in common clinical practice in kazakhstan.

this post-marketing observational study will be conducted in a prospective, multi-centre format. it is a non-interventional, observational study in which sevorane is prescribed for adult patients undergoing general surgery for induction and maintenance of anesthesia in the usual manner in accordance with the terms of the local marketing authorization. sevorane is used for induction and maintenance anesthesia by the choice of anesthesiologist. no additional procedures (other than standard of care) shall be applied to the patients. each patient will be observed from the start of anesthesia through anesthesia end. markers of myocardial ischemia will be detected up to the first 24 hours after anesthesia (if available). additionally the correlation between the experience and training background of anesthesiologists and patient related outcomes of general anesthesia with sevorane as a single anesthetic will be assessed.

Eligibility criteria:
inclusion criteria: * patients needing general anesthesia for planned or urgent surgery for whom sevorane is used for induction and maintenance anesthesia by the choice of anesthesiologist * age greater than or equal to 18 years exclusion criteria: * known sensitivity to sevoflurane or other anesthetic containing halogen * known or suspected genetic susceptibility to malignant hyperthermia * receiving regional anesthetic techniques * receiving intravenous anesthesia * a history of unexplained moderate/severe hepatic dysfunction with jaundice, fever, and/or eosinophilia in association with halogenated anesthetics

Keywords: general surgery general anesthesia inhalation anesthesia sevorane sevoflurane
cell-based therapy for white matter repair in periventricular leukomalacia

Conditions: Periventricular Leukomalacia; White Matter Disease; Hypoxic-Ischemic Encephalopathy; Demyelinating Diseases; Neonatal Encephalopathy

Summary: the goal of this study is to explore a new treatment that may help repair brain damage in individuals with periventricular leukomalacia (pvl), a condition that affects white matter in the brain. researchers are testing whether a combination of outer radial glia (org) cells and specific molecules can support brain repair. the main questions the study aims to answer are: can the treatment help regrow white matter and improve myelin repair? does the treatment reduce scarring in the brain? is the treatment safe and well-tolerated? the study uses several components, including: 20α-hydroxycholesterol to support cell function esi1 to help repair the myelin sheath chondroitinase abc to break down scar tissue in the brain researchers will study how these work together to protect and repair the brain by influencing specific pathways involved in damage and recovery.


Eligibility criteria:
inclusion criteria: * diagnosis of periventricular leukomalacia (pvl) confirmed by mri * clinically stable at time of intervention * parental or legal guardian consent if participant is a minor exclusion criteria: * severe congenital brain malformations unrelated to pvl * active cns infection or systemic inflammatory disease * history of severe intraventricular hemorrhage (grade iii/iv) * known allergy to any therapeutic components (e.g., chondroitinase abc) * participation in another interventional study within the past 30 days

Keywords: periventricular leukomalacia myelin repair white matter injury demyelination neonatal brain injury neuroregeneration cns regeneration brain repair neonatal hypoxia
telemedicine for children with sickle cell disease

Conditions: Anemia, Sickle Cell

Summary: the purpose of this study is to learn more about how the use of two different types of telemedicine (distance medical care) can address barriers to receiving comprehensive sickle cell care, and whether care can be improved. aim 1: adapt two telemedicine models (i.e., hub-and-spoke; direct-to-consumer) for use with children with scd using caregiver input from our preliminary k12 work. aim 2: demonstrate the feasibility of the telemedicine models developed in aim 1 as the models undergo successive stakeholder refinement during use in actual clinical care. aim 3: evaluate the effectiveness of the refined models from aim 2 in a pre/post study by assessing (a) process of care measures, (b) provider satisfaction, (c) caregiver/patient-centered outcomes, and (d) clinical outcomes and healthcare utilization.


Eligibility criteria:
inclusion criteria: * caregivers must be 18 years or older, who have children between 0 to 21 years old with a diagnosis of sickle cell disease and receive care at the riley hospital for children comprehensive sickle cell disease clinic. * adolescent patients 16 years and older are also able to participate in interviews/surveys. * the family must be willing to receive their care using the telemedicine model available to them based on the location of their primary residence. * telescd model participants must live within 1 hour of the pre-identified telemedicine sites, while virtualscd model participants must live within the city limits of the pre-identified area. exclusion criteria: * if a patient receives chronic transfusion therapy, they will not be eligible to participate, as our telemedicine models will not support this.
effect of baduanjin on functional performance in pre-frail/frail older adults

Conditions: Frailty; Frail Elderly Syndrome

Summary: the aim for this study is to investigate the effectiveness of a 16-week realistic community-delivered baduanjin training program compared to a waitlist control intervention, in improving functional outcomes among pre-frail and frail older adults in singapore. it is hypothesized that participants that receive 16-week of bdj training will have significant improvement in physical function (including balance, muscle strength, and endurance); alleviate exhaustion; reduce risk of falling and fear of falling; potentially reverse frailty; reduce depression; and improve quality of life, potentially with greater improvements in area(s) for individuals with lower baseline measures. whereas, participants in the waitlist control group, will have insignificant changes to their baseline measures.


Eligibility criteria:
inclusion criteria: * pre-frail and frail adults aged 55 years and above * able to ambulate (move about) without personal assistance and has no other physical limitations affecting participation and adherence * able to understand basic instructions * generally sedentary lifestyle exclusion criteria: * participating in other intervention studies * perform regular moderate to vigorous intensity exercise * perform regular taichi or qigong exercise * have severe audio-visual impairment * diagnosed with cognitive impairment (e.g. dementia, alzheimer's disease) and/or history of neurological disorder (e.g. cerebral palsy, parkinson's disease) * diagnosed with postural hypotension (have a drop of 20mmhg systolic blood pressure, or a drop of 10mmhg diastolic blood pressure within two to five minutes of standing up, or if standing causes signs and symptoms) * unable to participate for the full duration of the study * unable to come to the training site by himself/herself or by the help of caregivers * not suitable to participate in exercise as deemed by a medical doctor
thrust manipulation versus non-thrust manipulation

Conditions: Mechanical Low Back Pain

Summary: the objective of this study is to investigate the comparative benefit of thrust and non-thrust manipulation on a population of patients with low back pain. the investigators hypothesize that there will be no difference in 4 week outcomes or greater, between the two groups.

thrust manipulation is considered traditional spinal manipulation. nonthrust manipulation is considered mobilization. the mobilization will be used in a similar manner as in clinical practice and this differs from past studies.

Eligibility criteria:
inclusion criteria: * patients, age 18 and older, with mechanically producible low back pain, who attend care at a physical therapy outpatient setting, will be screened for eligibility for the study. * for patients to meet inclusion requirements, they had to display a within session change in pain and/or range of motion during the assessment phase of the clinical examination. in other words, as the clinician performed their assessment and applied a passive accessory assessment technique, the pain and/or range of motion improved during that session, which suggests a favorable outcome using a comparable treatment technique. this is hallmark clinical finding in the patient response model and has been proposed as both a predictor of a positive outcome and as a prognostic variable toward long-term improvements in impairments. exclusion criteria: * the presence of any red flags (i.e., tumor, metabolic diseases, ra, osteoporosis, prolonged history of steroid use, etc.) * signs consistent with nerve root compression (reproduction of low back or leg pain with straight leg raise at less than 45° * muscle weakness involving a major muscle group of the lower extremity, * diminished lower extremity muscle stretch reflex * diminished or absent sensation to pinprick in any lower extremity dermatome) * other exclusion criteria included prior surgery to the lumbar spine and current pregnancy

Keywords: manipulation mobilization low back pain treatment